Entera Bio ( (ENTX) ) has provided an announcement.
Entera Bio Ltd. announced its financial results and business updates for 2024, highlighting significant advancements in its oral peptide programs, including EB613 for osteoporosis, which is poised for a Phase 3 study pending FDA updates. The company also reported progress in its GLP-1/Glucagon and GLP-2 tablet programs, collaborating with OPKO Health to enhance its pipeline. Entera’s financial position was strengthened by investments, allowing it to fund operations into 2026, with a focus on regulatory and development activities.
More about Entera Bio
Entera Bio Ltd. is a leader in the development of oral peptides and protein replacement therapies, focusing on advancing treatments for conditions such as osteoporosis, obesity, metabolic disorders, short bowel syndrome, and hypoparathyroidism.
YTD Price Performance: -20.18%
Average Trading Volume: 118,930
Technical Sentiment Signal: Buy
Current Market Cap: $74.96M
For a thorough assessment of ENTX stock, go to TipRanks’ Stock Analysis page.